Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: LY01005|DRUG: ZOLADEX® 3.6 mg
Sponsor: Luye Pharma Group Ltd.